AAAAAA

   
Results: 1-13 |
Results: 13
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
Authors: Somlo, G Chow, W Hamasaki, V Leong, L Margolin, K Morgan, R Sniecinski, I Frankel, P Reardon, D Longmate, J Raschko, J Shibata, S O'Donnell, M Smith, E Tetef, M Forman, S Yen, Y Molina, A Doroshow, JH
Citation: G. Somlo et al., Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies, BIOL BLOOD, 7(5), 2001, pp. 284-293
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies
Authors: Tetef, ML Synold, TW Chow, W Leong, L Margolin, K Morgan, R Raschko, J Shibata, S Somlo, G Yen, Y Groshen, S Johnson, K Lenz, HJ Gandara, D Doroshow, JH
Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576
Using gadolinium-infusion MR venography to show the impalpable testis in pediatric patients
Authors: Lam, WWM Tam, PKH Ai, VHG Chan, KL Chan, FL Leong, L
Citation: Wwm. Lam et al., Using gadolinium-infusion MR venography to show the impalpable testis in pediatric patients, AM J ROENTG, 176(5), 2001, pp. 1221-1226
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy
Authors: Morgan, RJ Synold, T Carr, BI Doroshow, JH Womack, EP Shibata, S Somlo, G Raschko, J Leong, L McNamara, M Chow, W Tetef, M Margolin, K Akman, S Longmate, J
Citation: Rj. Morgan et al., Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy, CANC CHEMOT, 47(4), 2001, pp. 327-332
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
Authors: Morgan, RJ Doroshow, JH Leong, L Schriber, J Shibata, S Forman, S Hamasaki, V Margolin, K Somlo, G Alvarnas, J McNamara, M Longmate, J Raschko, J Chow, W Vasilev, S McGonigle, K Yen, Y
Citation: Rj. Morgan et al., Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer, BONE MAR TR, 28(9), 2001, pp. 859-863
Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis
Authors: Duffy, KJ Darcy, MG Delorme, E Dillon, SB Eppley, DF Erickson-Miller, C Giampa, L Hopson, CB Huang, YF Keenan, RM Lamb, P Leong, L Liu, NN Miller, SG Price, AT Rosen, J Shah, R Shaw, TN Smith, H Stark, KC Tian, SS Tyree, C Wiggall, KJ Zhang, L Luengo, JI
Citation: Kj. Duffy et al., Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis, J MED CHEM, 44(22), 2001, pp. 3730-3745
Differential expression of N- and B-cadherin during lens development
Authors: Leong, L Menko, AS Grunwald, GB
Citation: L. Leong et al., Differential expression of N- and B-cadherin during lens development, INV OPHTH V, 41(11), 2000, pp. 3503-3510
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up
Authors: Morgan, RJ Braly, P Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Najera, L Johnson, D Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up, GYNECOL ONC, 77(3), 2000, pp. 433-438
MR appearance of metastatic melanotic melanoma in the breast
Authors: Ho, LWC Wong, KP Chan, JHM Chow, LWC Leung, EYF Leong, L
Citation: Lwc. Ho et al., MR appearance of metastatic melanotic melanoma in the breast, CLIN RADIOL, 55(7), 2000, pp. 572-573
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial
Authors: Tetef, M Leong, L Ahn, C Akman, S Chow, W Margolin, K Morgan, RJ Raschko, J Shibata, S Somlo, G Doroshow, JH
Citation: M. Tetef et al., Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial, CANCER INV, 17(2), 1999, pp. 114-117
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up
Authors: Morgan, RJ Braly, P Cecchi, G Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Parker, P Stein, A Cho, J Smith, E Coluzzi, P Najera, L Johnson, D Womack, E Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up, GYNECOL ONC, 75(3), 1999, pp. 419-426
Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes
Authors: Tan, KCB Ai, VHG Chow, MS Chau, MT Leong, L Lam, KSL
Citation: Kcb. Tan et al., Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes, J CLIN END, 84(9), 1999, pp. 3212-3216
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
Authors: Somlo, G Sniecinski, I ter Veer, A Longmate, J Knutson, G Vuk-Pavlovic, S Bhatia, R Chow, W Leong, L Morgan, R Margolin, K Raschko, J Shibata, S Tetef, M Yen, Y Forman, S Jones, D Ashby, M Fyfe, G Hellmann, S Doroshow, JH
Citation: G. Somlo et al., Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy, BLOOD, 93(9), 1999, pp. 2798-2806
Risultati: 1-13 |